AC
Therapeutic Areas
Iovance Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Amtagvi (lifileucel) | Advanced melanoma (post-anti-PD-1) | Approved |
| Lifileucel | Advanced cervical cancer (post-chemotherapy) | Phase 2 |
| Lifileucel + Pembrolizumab | Advanced frontline melanoma | Phase 3 |
| LN-145 (TIL therapy) | Advanced non-small cell lung cancer (NSCLC) | Phase 2 |
| TIL therapy | Advanced endometrial cancer | Phase 2 |
| Genetically modified TIL therapies | Solid tumor cancers | Preclinical |
Leadership Team at Iovance Biotherapeutics
FG
Frederick G. Vogt, Ph.D., J.D.
Interim CEO, President and General Counsel
CR
Corleen Roche
Chief Financial Officer
FG
Friedrich Graf Finckenstein, M.D.
Chief Medical Officer
ID
Iain Dukes, D.Phil.
Chairman of the Board
SR
Steven Rosenberg, M.D., Ph.D.
Research Partner (NCI)